Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $90

Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $50 to $90.